Date: 2017-09-25
Type of information: Financing round
Company: Deep Genomics (Canada)
Investors: Khosla Ventures (USA - CA) True Ventures (USA - CA)
Amount: $13 million
Funding type: financing round
Planned used:
- In the next three years, Deep Genomics will use its platform to unlock new classes of anti-sense oligonucleotide therapies that were previously inaccessible, and advance them for clinical evaluation.
- Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. In project Saturn, named after the god of plenty and renewal, the platform will be used to search across a vast space of over 69 billion molecules and to generate a library of 1000 compounds that can be used to precisely manipulate cell biology. This technology will enable Deep Genomics to identify preclinical candidates and to advance them for clinical evaluation in collaboration with stakeholders.
Others:
- • On September 25, 2017, Deep Genomics, the AI driven genetic medicine company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by early stage investment firm True Ventures.
- Deep Genomics joins Khosla Ventures’ portfolio, which includes Climate Corporation, Editas Medicine, Guardant Health and Square.
Therapeutic area: Technology - Services
Is general: Yes
